<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675633</url>
  </required_header>
  <id_info>
    <org_study_id>FEUrea in liver cirrhosis</org_study_id>
    <nct_id>NCT03675633</nct_id>
  </id_info>
  <brief_title>Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Liver Cirrhosis</brief_title>
  <official_title>Fractional Excretion of Urea: an Excellent Simple Tool for the Differential Diagnosis of Acute Kidney Injury in Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the diagnostic performance of FEUrea for the&#xD;
      differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the&#xD;
      ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AKI according to KDIGO guidelines is defined as the followings:&#xD;
&#xD;
        -  An increase in serum creatinine by ≥0.3 mg/dl (≥26.5 µmol/l) within 48 h&#xD;
&#xD;
        -  An increase in serum creatinine to ≥1.5 times baseline within the previous 7 days&#xD;
&#xD;
        -  Urine volume ≤0.5 ml/kg/h for 6 h Serum creatinine overestimates renal function in&#xD;
           cirrhotic patients due to a number of factors: Creatinine production in patients with&#xD;
           cirrhosis is reduced due to muscle wasting, there is an increased secretion of&#xD;
           creatinine in the renal tubules, sCr may be diluted due to an increased volume of&#xD;
           distribution, and finally, high bilirubin levels may interfere with the assays to&#xD;
           measure its level. Recently, the International Club of Ascites (ICA) has adopted the&#xD;
           concept of AKI which was developed originally to be used in general critically-ill&#xD;
           patients. AKI is defined as the increase of at least 0.3 mg/dL (26 μmol/L) and/or ≥ 50%&#xD;
           from baseline, within 48 hours Since urea absorption is largely modulated in the&#xD;
           proximal tubules, it is not affected by diuretics acting more distally. The&#xD;
           investigators therefore hypothesized that the fractional excretion of urea (FEUrea)&#xD;
           could serve as a clinical aid in making an early distinction between ATN versus Pre&#xD;
           renal azotemia and HRS type 1 in patients with cirrhosis and ascites presenting with AKI&#xD;
           Fractional excretion of urea (FEUrea) ([urine urea nitrogen/ blood urea nitrogen)/(urine&#xD;
           creatinine/plasma creatinine)] X 100) &lt; 35% is specific for prerenal azotemia, and &gt; 50%&#xD;
           is specific for ATN&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of FEUrea in different types of AKI in liver cirrhosis</measure>
    <time_frame>baseline</time_frame>
    <description>measurement of FEUrea in different types of AKI in decompansated liver cirrhosis to identify its cause</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>FEUrea in decompensated liver cirrhosis</arm_group_label>
    <description>FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FEUrea</intervention_name>
    <description>FEUrea in decompansated liver cirrhosis</description>
    <arm_group_label>FEUrea in decompensated liver cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        compensated and decompensated rrhotic patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis of any etiology diagnosed by clinical parameters involving laboratory&#xD;
             tests, endoscopic or radiologic evidence of cirrhosis,&#xD;
&#xD;
          -  History of decompensation (hepatic encephalopathy, ascites, variceal bleeding,&#xD;
             jaundice)&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
          -  Presence of moderate or severe ascites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients excluded from analysis were those who did not meet inclusion criteria as well as&#xD;
        the following&#xD;
&#xD;
          -  Prior liver or kidney transplant,&#xD;
&#xD;
          -  Advanced chronic kidney disease G4(GFR category grade 4) according to KDIGO&#xD;
             guidelines.&#xD;
&#xD;
          -  Patients on acute or chronic renal replacement therapy,&#xD;
&#xD;
          -  Ambiguous diagnosis of AKI and phenotype of AKI,&#xD;
&#xD;
          -  Patients with hepatocellular carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nermeen Mobarez, specialist</last_name>
    <phone>00201098800485</phone>
    <email>nermeenmobarez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Essam Abdel Aziz, lecturer</last_name>
    <phone>00201009699081</phone>
    <email>essam.nephro@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Piano S, Brocca A, Angeli P. Renal Function in Cirrhosis: A Critical Review of Available Tools. Semin Liver Dis. 2018 Aug;38(3):230-241. doi: 10.1055/s-0038-1661372. Epub 2018 Jul 24. Review.</citation>
    <PMID>30041275</PMID>
  </reference>
  <reference>
    <citation>Durand F, Olson JC, Nadim MK. Renal dysfunction and cirrhosis. Curr Opin Crit Care. 2017 Dec;23(6):457-462. doi: 10.1097/MCC.0000000000000457. Review.</citation>
    <PMID>29023314</PMID>
  </reference>
  <reference>
    <citation>Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017 May;5(2):127-137. doi: 10.1093/gastro/gox009. Epub 2017 Apr 24.</citation>
    <PMID>28533910</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 15, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Nermeen mahmoud mobarez</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

